Clinical trial · Interventional
Comparing Health Services Interventions for the Prevention of HPV-related Cancer
Work Package 4: HPV Vaccination of Women in Screening Ages
NCT02837926CI-TRIAL-00038058CoheaHr-WP4completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to identify global and local determinants of HPV vaccine acceptability, HPV vaccine uptake and compliance as well as identify logistics and programmatic issues in each country to offer the HPV vaccine, as a potential cervical cancer prevention strategy, to mid-aged women attending screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cervarix® | Biological | — | UNRESOLVED |
| Gardasil vaccine | Biological | — | UNRESOLVED |
| questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- women attending for cervical cancer screening
- interventionNames
- Other: questionnaire
- Biological: Gardasil vaccine
- Biological: Cervarix®
Primary outcomes (1)
- measure
- number of vaccinated patients
- timeFrame
- up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * women within the age range of 25-45 * attending cervical cancer screening Exclusion Criteria: * previous history of HPV vaccine administration
References
Publications (0)
Data not yet available
No reference posted for this study.